A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cytotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/14653249.2010.515582PMID 20849361PMCID PMC3760671
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systematic analysis of interference due to stutter in estimating chimerism following hematopoietic cell transplantation

  2009cited by this paper
• Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.

  2009cited by this paper
• Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

  2009cited by this paper
• Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.

  2009cited by this paper
• Adoptive cell therapy for the treatment of patients with metastatic melanoma.

  2009cited by this paper
• Tumor-Induced CD11b+Gr-1+ Myeloid Cells Suppress T Cell Sensitization in Tumor-Draining Lymph Nodes1

  2008cited by this paper
• Adoptively-Infused NK Cells Maintain Their Antitumor Effects in Vivo in the Presence of CyclosporineA (CSA)

  2008cited by this paper
• Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008cited by this paper
• Successful Haploidentical Hematopoietic Cell Engraftment Using a Non-Myeloablative Preparative Regimen Including Natural Killer (NK) Cells

  2008cited by this paper
• Strategies to Overcome Obstacles to Successful Immunotherapy of Melanoma

  2008cited by this paper
• No Job Name

  2007cited by this paper
• DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.

  2007cited by this paper
• Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy

  2007cited by this paper
• Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

  2006cited by this paper
• Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer.

  2006cited by this paper
• Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

  2005cited by this paper
• Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

  2005cited by this paper
• CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

  2005cited by this paper
• Patients with malignancy requiring urgent therapy: CASE 3. Tumor lysis syndrome associated with chemotherapy in ovarian cancer.

  2005cited by this paper
• Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.

  2005cited by this paper
• Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo

  2005cited by this paper
• Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

  2005cited by this paper
• Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

  2005cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract

  2004cited by this paper
• Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells

  2004cited by this paper
• Severe hemolysis due to passenger lymphocyte syndrome after hematopoietic stem cell transplantation from an HLA-matched related donor.

  2003cited by this paper
• Making room for T cells.

  2002cited by this paper
• T cell homeostasis and systemic autoimmunity.

  2001cited by this paper
• Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

  2001cited by this paper
• Regulatory CD 4 1 CD 25 1 T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer 1

  2001cited by this paper
• Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

  2001cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

  1999cited by this paper
• Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

  1999cited by this paper
• Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

  1997cited by this paper
• Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-beta 1 and independent accessory cell-derived contact and soluble factors.

  1996cited by this paper
• Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.

  1996cited by this paper
• Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.

  1996cited by this paper
• Production of Human Natural Killer Cells for Adoptive Immunotherapy Using a Computer-Controlled Stirred-Tank Bioreactor

  1996cited by this paper
• CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.

  1996cited by this paper
• Express yourself or die: peptides, MHC molecules, and NK cells.

  1995cited by this paper
• Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.

  1995cited by this paper
• Natural killer cell receptors: the offs and ons of NK cell recognition.

  1995cited by this paper
• Natural Killer Cell Proliferation Is Dependent on Human Serum and Markedly Increased Utilizing an Enriched Supplemented Basal Medium

  1995cited by this paper
• Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy.

  1994cited by this paper
• Population dynamics of human activated natural killer cells in culture

  1994cited by this paper
• Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor.

  1994cited by this paper
• Tumor Lysis Syndrome in Nonhematologic Malignancies: Report of a Case and Review of the Literature

  1994cited by this paper
• P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities

  1993cited by this paper
• Tumor lysis syndrome after combination chemotherapy for ovarian cancer.

  1993cited by this paper
• Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.

  1992cited by this paper
• The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.

  1992cited by this paper
• Role of monocytes in the expansion of human activated natural killer cells.

  1992cited by this paper
• Recombinant IL‐2‐activated NK cells mediate LAK activity against ovarian cancer

  1988cited by this paper
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper

• Agent-based modeling of cellular dynamics in adoptive cell therapy.

  2026cites this paper
• From innate immunity to precision cancer therapy: the clinical advancement of NK cell therapy.

  2026cites this paper
• Breast Cancer Multicellular Spheroid Models—A Tool for Studying Cancer Biology; a Possible Platform for Drug Screening and Personalized Medicine

  2026cites this paper
• Agent-based modeling of cellular dynamics in adoptive cell therapy

  2025cites this paper
• Natural Killer (NK) Cell-Based Therapies Have the Potential to Treat Ovarian Cancer Effectively by Targeting Diverse Tumor Populations and Reducing the Risk of Recurrence

  2025cites this paper
• Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy

  2025cites this paper
• Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control

  2025cites this paper
• Unraveling the breast cancer tumor microenvironment: crucial factors influencing natural killer cell function and therapeutic strategies

  2025cites this paper
• Natural killer cell–based immunotherapy for cancer

  2025cites this paper
• Recent advances in tumor immunotherapy based on NK cells

  2025cites this paper
• 3D Chemotaxis Chip for Investigating Natural Killer Cell Migration Mechanisms

  2025cites this paper
• Natural Killer Cell Therapy Combined with Probiotic Bacteria Supplementation Restores Bone Integrity in Cancer by Promoting IFN-γ Production

  2025cites this paper
• Supercharged NK cells: a unique population of NK cells capable of differentiating stem cells and lysis of MHC class I high differentiated tumors

  2025cites this paper
• The Roles of Natural Killer Cells in Breast Cancer Pathobiology and their Regulation by Estrogens.

  2025cites this paper
• Targeting Ovarian Neoplasms: Subtypes and Therapeutic Options

  2025cites this paper
• A patient-derived ovarian cancer organoid platform to study susceptibility to natural killer cells

  2025cites this paper
• NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study

  2025cites this paper
• Mitochondrial dynamics and metabolic attributes regulate function of natural killer cell and infiltration in tumor microenvironment modulating disease progression.

  2025cites this paper
• Supercharged Natural Killer (sNK) Cells Inhibit Melanoma Tumor Progression and Restore Endogenous NK Cell Function in Humanized BLT Mice

  2025cites this paper
• CAR therapies: development, design, and implementation.

  2025cites this paper
• Good manufacturing practice production of an off-the-shelf CD34+ progenitor-derived NK cell product with preserved anti-tumor functionality post-infusion in NOD/SCID/IL2Rgnull mice

  2025cites this paper
• Super-Charged Natural Killer Cells: A Promising Immunotherapeutic Strategy for Oral Cancer

  2025cites this paper
• M1 macrophage-engineered vesicles have anti-cancer activity in ovarian cancer

  2025cites this paper
• Advances in Induced Pluripotent Stem Cell-Derived Natural Killer Cell Therapy

  2024cites this paper
• Clinical Application of Umbilical Cord Blood NK Cells in the Treatment of Liver Cancer

  2024cites this paper
• Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies

  2024cites this paper
• Adoptive T cell therapy for ovarian cancer.

  2024cites this paper
• Sequential Autologous CIK/NK Cells Combined with Chemotherapy to Induce Long-Term Tumor Control in Advanced Rectal Cancer: A Case Report

  2024cites this paper
• Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas

  2024influential citation
• The Function of the Immune System, Beyond Strategies Based on Cell‐Autonomous Mechanisms, Determines Cancer Development: Immune Response and Cancer Development

  2024cites this paper
• An improved approach to generate IL-15+/+/TGFβR2−/− iPSC-derived natural killer cells using TALEN

  2024cites this paper
• Natural killer cell-based cancer immunotherapy: from basics to clinical trials

  2024cites this paper
• NK cell-derived exosomes inhibit survival of Mycobacterium tuberculosis by promoting apoptosis in mice.

  2024cites this paper
• Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis

  2024cites this paper
• Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment

  2024cites this paper
• Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics

  2024cites this paper
• Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization

  2024cites this paper
• Interleukin signaling in the regulation of natural killer cells biology in breast cancer

  2024cites this paper
• Process engineering of natural killer cell-based immunotherapy.

  2023cites this paper
• Advances in natural killer cell therapies for breast cancer

  2023influential citation
• Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia

  2023cites this paper
• Translation of Cell Therapies to Treat Autoimmune Disorders.

  2023cites this paper
• A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome

  2023cites this paper
• Beyond immunotherapy—treatment advances in cell-based therapy for ovarian cancer and associated challenges

  2023cites this paper
• Use of CD122+ natural killer cell precursors for superior anti-leukemia responses

  2023cites this paper
• IPSC-derived CAR-NK cells for cancer immunotherapy.

  2023cites this paper
• Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches

  2023cites this paper
• Natural killer cell epigenetic reprogramming in tumors and potential for cancer immunotherapy.

  2023cites this paper
• Natural killer cells at the forefront of cancer immunotherapy with immune potency, genetic engineering, and nanotechnology.

  2023cites this paper
• Ovarian cancer treatment and natural killer cell-based immunotherapy

  2023cites this paper
• The effect of mitochondria inhibition on natural killer cells cytotoxicity in triple-negative breast cancer cells.

  2023cites this paper
• NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics?

  2023cites this paper
• CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma

  2023cites this paper
• The application, safety, and future of ex vivo immune cell therapies and prognosis in different malignancies

  2023cites this paper
• Supercharged NK Cell-Based Immuotherapy in Humanized Bone Marrow Liver and Thymus (Hu-BLT) Mice Model of Oral, Pancreatic, Glioblastoma, Hepatic, Melanoma and Ovarian Cancers.

  2023cites this paper
• Identification of Tissue-Resident Natural Killer and T Lymphocytes with Anti-Tumor Properties in Ascites of Ovarian Cancer Patients

  2023cites this paper
• Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia

  2023cites this paper
• Cancer immunotherapy via stem cell-derived NK cells.

  2023cites this paper
• Effector and cytolytic function of natural killer cells in anti-cancer immunity.

  2023cites this paper
• Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

  2023cites this paper
• An optimized cultivation method for future in vivo application of γδ T cells

  2023cites this paper
• CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer

  2022cites this paper
• Harnessing NK Cells to Control Metastasis

  2022cites this paper
• Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy

  2022cites this paper
• Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: A novel orientation for immunotherapy

  2022cites this paper
• The prospect of genetically engineering natural killer cells for cancer immunotherapy

  2022influential citation
• Targeting purine metabolism in ovarian cancer

  2022cites this paper
• Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment

  2022cites this paper
• Clinical relevance of natural killer cells in breast cancer

  2022cites this paper
• A general toxicity and biodistribution study of human natural killer cells by single or repeated intravenous dose in severe combined immune deficient mice

  2022cites this paper
• Scale-out production of extracellular vesicles derived from natural killer cells via mechanical stimulation in a seesaw-motion bioreactor for cancer therapy

  2022cites this paper
• Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought

  2022cites this paper
• NAD+ salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity

  2022influential citation
• Tracking of NK Cells by Positron Emission Tomography Using 89Zr-Oxine Ex Vivo Cell Labeling.

  2022cites this paper
• CAR-NK cells for cancer immunotherapy: from bench to bedside

  2022cites this paper
• Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis.

  2022cites this paper
• Better by design: What to expect from novel CAR-engineered cell therapies?

  2022cites this paper
• Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer

  2022cites this paper
• The next wave of cellular immunotherapies in pancreatic cancer

  2022cites this paper
• Advances in NK cell production

  2022cites this paper
• Clinical grade production of IL‐15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post‐transplant cyclophosphamide

  2022cites this paper
• Assessing the Future of Solid Tumor Immunotherapy

  2022cites this paper
• Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy

  2022cites this paper
• Overcoming tumor resistance mechanisms in CAR-NK cell therapy

  2022cites this paper
• Progression-Free Survival of a Patient with Advanced Hepatocellular Carcinoma Treated with Adoptive Cell Therapy Using Natural Killer Cells: A Case Report

  2022cites this paper
• NK cells and CD8 T cells in cancer immunotherapy: Similar functions by different mechanisms

  2021cites this paper
• Understanding and Improving Cellular Immunotherapies Against Cancer: From Cell-Manufacturing to Tumor-Immune Models.

  2021cites this paper
• Cloning and expressing of interleukine 2 in amniotic membrane-derived mesenchymal stem cells, as a potent feeder layer

  2021cites this paper
• Detection and viability of murine NK cells in vivo in a lymphoma model using fluorine‐19 MRI

  2021cites this paper
• Non-invasive and label-free identification of human natural killer cell subclasses by biophysical single-cell features in microfluidic flow.

  2021cites this paper
• Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies

  2021cites this paper
• CAR-NK Cells in the Treatment of Solid Tumors

  2021cites this paper
• Cell therapies in ovarian cancer

  2021cites this paper
• Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice

  2021cites this paper
• Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia

  2021cites this paper
• International Journal of Medical Science and Current Research (IJMSCR)

  2021cites this paper
• Infusion reactions in natural killer cell immunotherapy: a retrospective review.

  2021cites this paper
• Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer

  2021cites this paper
• Live cell imaging of highly activated natural killer cells against human hepatocellular carcinoma in vivo.

  2021cites this paper
• Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment.

  2021cites this paper